Cargando…

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study

PURPOSE: Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is steadily increasing due to widespread asbestos exposure. There is still no effective therapy for MPM. Pemetrexed (Pe) is one of the few chemotherapeutic agents approved for advanced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cova, Emanuela, Pandolfi, Laura, Colombo, Miriam, Frangipane, Vanessa, Inghilleri, Simona, Morosini, Monica, Mrakic-Sposta, Simona, Moretti, Sarah, Monti, Manuela, Pignochino, Ymera, Benvenuti, Silvia, Prosperi, Davide, Stella, Giulia, Morbini, Patrizia, Meloni, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361319/ https://www.ncbi.nlm.nih.gov/pubmed/30774332 http://dx.doi.org/10.2147/IJN.S186344

Ejemplares similares

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
por: Pignochino, Ymera, et al.
Publicado: (2015)

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis
por: Stella, Giulia M., et al.
Publicado: (2014)

5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin
por: Bosio, Matteo, et al.
Publicado: (2018)

Loading Imatinib inside targeted nanoparticles to prevent Bronchiolitis Obliterans Syndrome
por: Pandolfi, Laura, et al.
Publicado: (2020)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

R(+)-Thioctic Acid Effects on Oxidative Stress and Peripheral Neuropathy in Type II Diabetic Patients: Preliminary Results by Electron Paramagnetic Resonance and Electroneurography
por: Mrakic-Sposta, Simona, et al.
Publicado: (2018)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study
por: Di Carlo, Stefano, et al.
Publicado: (2016)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

Evaluation of Oxidative Stress and Metabolic Profile in a Preclinical Kidney Transplantation Model According to Different Preservation Modalities
por: Simona, Mrakic-Sposta, et al.
Publicado: (2023)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
por: Federico, Rea, et al.
Publicado: (2013)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
por: Wu, Mindan, et al.
Publicado: (2023)

miRNAs Potentially Involved in Post Lung Transplant-Obliterative Bronchiolitis: The Role of miR-21-5p
por: Bozzini, Sara, et al.
Publicado: (2021)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
por: Ceresoli, G L, et al.
Publicado: (2008)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Editorial: Women in environmental physiology 2022
por: Eftedal, Ingrid, et al.
Publicado: (2023)

Oxygen Variations—Insights into Hypoxia, Hyperoxia and Hyperbaric Hyperoxia—Is the Dose the Clue?
por: Balestra, Costantino, et al.
Publicado: (2023)

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
por: Moro, Jacopo, et al.
Publicado: (2022)

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
por: Mairinger, Fabian Dominik, et al.
Publicado: (2017)

Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience
por: Falanga, Francesco, et al.
Publicado: (2022)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach
por: Lisini, Daniela, et al.
Publicado: (2021)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Comment on Menzel et al. Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice—Which to Use Regarding Disease Outcomes? Antioxidants 2021, 10, 414
por: Mrakic-Sposta, Simona, et al.
Publicado: (2021)

Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy
por: Goracci, Martina, et al.
Publicado: (2020)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
por: Forde, Patrick M., et al.
Publicado: (2021)

Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways
por: Sun, Rong, et al.
Publicado: (2022)

Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
por: Kutuk, Tugce, et al.
Publicado: (2022)

Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
por: Seifi, Sharareh, et al.
Publicado: (2023)

Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study
por: Saracino, Laura, et al.
Publicado: (2021)

Oxidative Stress Assessment in Response to Ultraendurance Exercise: Thiols Redox Status and ROS Production according to Duration of a Competitive Race
por: Vezzoli, Alessandra, et al.
Publicado: (2016)

Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge
por: Abbott, David Michael, et al.
Publicado: (2020)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ag8og46ccjqer0po8b784jlbg7